Opportunity Information: Apply for PAR 10 231
Apply for PAR 10 231
- The National Institutes of Health in the health income security and social services sector is offering a public funding opportunity titled "Innovative Therapies and Tools for Screenable Disorders in Newborns (R03)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.865 Child Health and Human Development Extramural Research.
- This funding opportunity was created on Jul 19, 2010 and posted on Jul 19, 2010.
- Applicants must submit their applications by Sep 7, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Public and State controlled institutions of higher education Special district governments Independent school districts State governments City or township governments Small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Others (see text field entitled Additional Information on Eligibility for clarification) Private institutions of higher education County governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Innovative Therapies and Tools for Screenable Disorders in Newborns (R03) opportunity (PAR-10-231) is an NIH/NICHD funding announcement focused on jump-starting smaller, targeted research projects that can speed progress on treatments and enabling tools for disorders relevant to newborn screening. The central idea is practical: newborn screening is most valuable when early detection can lead to an effective intervention, so this program encourages research that strengthens the scientific and translational foundation needed to treat conditions that are already screened, as well as certain genetic conditions that could realistically become screenable in the near future if an effective therapy is developed.
A key concept in the announcement is the definition of a "high priority" condition. NICHD describes these as genetic disorders where the existence (or development) of an efficacious therapy would make the disorder suitable for newborn screening. In other words, the research emphasis is not only on improving screening itself, but also on building the therapeutic and technical ecosystem that makes screening meaningful: better interventions, better supporting technologies, and better methods that help move a condition from "detectable" to "actionable" during the newborn period.
This FOA uses the NIH Small Research Grant (R03) mechanism, which is designed for compact projects that can be completed relatively quickly with limited resources. The R03 mechanism commonly supports pilot and feasibility studies, small self-contained projects, secondary analyses of existing datasets, and the development of research methods or new research technologies. In practice, this means NICHD is looking for early-stage or tightly scoped work that can generate proof-of-concept results, validate an approach, de-risk a larger future project, or produce a usable tool or method that directly supports therapy development or the broader newborn screening pipeline.
The announcement notes that this R03 opportunity runs in parallel with two companion FOAs that have the same scientific scope but use different grant mechanisms (R01 and R21; PAR-10-230 and PAR-10-232). That structure is meant to give applicants multiple entry points depending on project maturity and scale: the R03 for smaller, faster efforts; the R21 typically for exploratory/developmental work; and the R01 for more substantial, fully developed projects.
Funding levels and the number of awards are not fixed in the text provided. NICHD indicates that award size and project duration will vary depending on the nature and scope of the proposed research, and that the final number of awards and total dollars will depend on factors such as the mix of applications received, scientific merit, project duration, and proposed budgets. In other words, applicants should expect standard NIH competition where funding decisions reflect application quality and programmatic fit rather than a preset quota.
Eligibility is broad and includes many types of U.S. and non-U.S. organizations. Examples listed include public and private institutions of higher education, nonprofits (including 501(c)(3) and other nonprofit structures), for-profit organizations (including small businesses and other for-profits), state and local governments (states, counties, cities/townships), independent school districts, special district governments, tribal governments and tribal organizations, public housing authorities/Indian housing authorities, and a range of other entities specifically called out such as HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian Serving Institutions, tribally controlled colleges and universities, faith-based/community-based organizations, U.S. territories/possessions, regional organizations, eligible federal agencies, and foreign (non-U.S.) organizations.
Administratively, the opportunity was posted July 19, 2010, with an original and final closing date of September 7, 2013, and an archive date of October 8, 2013, meaning it is no longer accepting applications under those dates. The sponsoring agency is the National Institutes of Health, with NICHD as the issuing institute, and the program sits under CFDA 93.865 (Child Health and Human Development Extramural Research). There is no cost sharing or matching requirement stated. For full details, the announcement points to the NIH Grants Guide page for PAR-10-231 and provides NIH Office of Extramural Research (OER) webmaster contacts for access or linking issues.
Frequently Asked Questions (FAQs)
What is the Innovative Therapies and Tools for Screenable Disorders in Newborns (R03) opportunity?
It is an NIH/NICHD funding announcement (PAR-10-231) intended to jump-start smaller, targeted research projects that accelerate progress on treatments and enabling tools for disorders relevant to newborn screening.
What is the main goal of this funding announcement?
The goal is to strengthen the treatment and technology foundation that makes newborn screening meaningful. The program emphasizes that screening is most valuable when early detection can lead to an effective intervention, so it supports research that helps move conditions from being merely detectable to being actionable in the newborn period.
Is this program focused on improving newborn screening tests themselves?
Not exclusively. While newborn screening is the context, the emphasis described here is on practical advances that make screening useful, including therapies, enabling tools, and methods that support translation from early detection to early intervention.
What types of conditions does NICHD consider a "high priority" focus for this program?
NICHD describes "high priority" conditions as genetic disorders where the existence (or development) of an efficacious therapy would make the disorder suitable for newborn screening. The idea is that having an effective treatment can make a condition realistic for screening because detection would lead to timely action.
Does the opportunity support research for conditions that are already part of newborn screening panels?
Yes. The description includes strengthening the scientific and translational foundation needed to treat conditions that are already screened.
Does the opportunity also support work on conditions not currently screened?
Yes, within the scope described. It includes certain genetic conditions that could realistically become screenable in the near future if an effective therapy is developed.
What grant mechanism does this opportunity use?
This FOA uses the NIH Small Research Grant (R03) mechanism.
What is the R03 mechanism designed to support?
The R03 mechanism is designed for compact projects that can be completed relatively quickly with limited resources. It commonly supports pilot and feasibility studies, small self-contained projects, secondary analyses of existing datasets, and the development of research methods or new research technologies.
What kinds of project outcomes does NICHD seem to be looking for under this R03?
Based on the description provided, NICHD is looking for early-stage or tightly scoped work that can generate proof-of-concept results, validate an approach, de-risk a larger future project, or produce a usable tool or method that supports therapy development or the broader newborn screening pipeline.
Are there related funding opportunities with the same scientific scope?
Yes. This R03 opportunity runs in parallel with two companion FOAs with the same scientific scope that use different grant mechanisms: an R01 (PAR-10-230) and an R21 (PAR-10-232).
How should an applicant think about choosing between the R03, R21, and R01 options mentioned?
The structure is intended to provide multiple entry points depending on project maturity and scale: the R03 is for smaller, faster efforts; the R21 is typically for exploratory/developmental work; and the R01 is for more substantial, fully developed projects.
How much funding is available, and how many awards will be made?
The text provided does not set fixed funding levels or a fixed number of awards. NICHD indicates that award size and project duration will vary depending on the nature and scope of the proposed research, and that the number of awards and total dollars will depend on factors such as the mix of applications received, scientific merit, project duration, and proposed budgets.
Is this a competitive NIH funding opportunity?
Yes. The description indicates a standard NIH competitive process where funding decisions reflect application quality and programmatic fit rather than a preset quota.
Who is the sponsoring agency and which NIH institute is issuing the announcement?
The sponsoring agency is the National Institutes of Health (NIH), and the issuing institute is NICHD (Eunice Kennedy Shriver National Institute of Child Health and Human Development).
What is the CFDA number associated with this program?
The program sits under CFDA 93.865 (Child Health and Human Development Extramural Research).
What types of organizations are eligible to apply?
Eligibility is broad and includes many U.S. and non-U.S. organizations. Examples listed include public and private institutions of higher education; nonprofits (including 501(c)(3) and other nonprofit structures); for-profit organizations (including small businesses and other for-profits); state and local governments (states, counties, cities/townships); independent school districts; special district governments; tribal governments and tribal organizations; public housing authorities/Indian housing authorities; and other entities specifically called out such as HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian Serving Institutions, tribally controlled colleges and universities, faith-based/community-based organizations, U.S. territories/possessions, regional organizations, eligible federal agencies, and foreign (non-U.S.) organizations.
Are foreign (non-U.S.) organizations eligible?
Yes. Foreign (non-U.S.) organizations are explicitly listed as eligible in the information provided.
Does the opportunity require cost sharing or matching funds?
No cost sharing or matching requirement is stated in the information provided.
When was the opportunity posted, and what were the closing dates?
The opportunity was posted on July 19, 2010. The original and final closing date listed is September 7, 2013, and the archive date is October 8, 2013.
Is this funding opportunity still accepting applications?
No. Based on the dates provided (final closing date September 7, 2013, and archive date October 8, 2013), it is no longer accepting applications under those dates.
Where can applicants find the official full announcement details?
The information provided points to the NIH Grants Guide page for PAR-10-231 for full details.
Who should be contacted for issues accessing or linking to the announcement page?
The announcement provides NIH Office of Extramural Research (OER) webmaster contacts for access or linking issues.
Browse more opportunities from the same category: Health Income Security and Social Services
Next opportunity: Innovative Therapies and Tools for Screenable Disorders in Newborns (R21)
Previous opportunity: Innovative Therapies and Tools for Screenable Disorders in Newborns (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 10 231
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 10 231) also looked into and applied for these:
| Funding Opportunity |
|---|
| Developmental Mechanisms of Human Structural Birth Defects (P01) Apply for RFA HD 10 006 Funding Number: RFA HD 10 006 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $900,000 |
| NICHD Program Project Grant (P01) Apply for PAR 10 245 Funding Number: PAR 10 245 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Molecular Mechanisms of Adverse Metabolic Drug Effects in Children and Adolescents (R01) Apply for RFA HD 10 010 Funding Number: RFA HD 10 010 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $250,000 |
| Dual Purpose with Dual Benefit Research in Biomedicine and Agriculture Using Agriculturally Important Domestic Species (R01) Apply for PAR 10 276 Funding Number: PAR 10 276 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Identifying and Understanding Effective Interventions for Orphans and Vulnerable Children Affected by HIV/AIDS (R01) Apply for RFA HD 10 017 Funding Number: RFA HD 10 017 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Preclinical Research on Model Organisms to Predict Treatment Outcomes for Disorders Associated with Intellectual and Developmental Disabilities (R01) Apply for PAR 11 038 Funding Number: PAR 11 038 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Understanding and Treating Co Morbid Conditions in Adolescents with Intellectual and Developmental Disabilities (R01) Apply for PA 11 039 Funding Number: PA 11 039 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Understanding and Treating Co Morbid Conditions in Adolescents with Intellectual and Developmental Disabilities (R03) Apply for PA 11 040 Funding Number: PA 11 040 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Understanding and Treating Co Morbid Conditions in Adolescents with Intellectual and Developmental Disabilities (R21) Apply for PA 11 041 Funding Number: PA 11 041 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| Specialized Cooperative Centers Program in Reproduction and Infertility Research (U54) Apply for RFA HD 12 169 Funding Number: RFA HD 12 169 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Outcome Measures for Use in Treatment Trials for Individuals with Intellectual and Developmental Disabilities (R01) Apply for PAR 11 045 Funding Number: PAR 11 045 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Indo US Collaborative Program on Low Cost Medical Devices (R03) Apply for PAR 11 044 Funding Number: PAR 11 044 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Mechanisms of Adverse Drug Reactions in Children (R01) Apply for PAR 11 051 Funding Number: PAR 11 051 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Mechanisms of Adverse Drug Reactions in Children (R03) Apply for PAR 11 052 Funding Number: PAR 11 052 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Studies in Neonatal Hypoglycemia (R03) Apply for PA 11 054 Funding Number: PA 11 054 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Studies in Neonatal Hypoglycemia (R01) Apply for PA 11 053 Funding Number: PA 11 053 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Studies in Neonatal Hypoglycemia (R21) Apply for PA 11 055 Funding Number: PA 11 055 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| Mentored Patient Oriented Research Career Development Award in Muscular Dystrophy Research (K23) Apply for PA 11 076 Funding Number: PA 11 076 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| NIH Pathway to Independence Award in Muscular Dystrophy Research (K99/R00) Apply for PA 11 078 Funding Number: PA 11 078 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Mentored Clinical Scientist Research Career Development Award in Muscular Dystrophy Research (K08) Apply for PA 11 077 Funding Number: PA 11 077 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 10 231", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.